Anaphylactic reaction to recombinant insulin-like growth factor-I

Journal of Pediatric Endocrinology and Metabolism

Volumn 21, Issue 4, 2008, Pages 381-384

  Torjusen, Erika ^a   Calderon, Jose ^a   Rivkees, Scott A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic reaction; Growth hormone; IGF I; Laron syndrome

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; GROWTH HORMONE; OXYGEN; PREDNISONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADOLESCENT; ANAPHYLAXIS; ARTICLE; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; INJECTION SITE RASH; LARON SYNDROME; MALE; ORAL PRURITUS; PRICK TEST; PROVOCATION TEST; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; RHINORRHEA; SIDE EFFECT; SKIN TEST; SNEEZING; URTICARIA;

EID: 44949255145     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2008.21.4.381     Document Type: Article

References (19)

1. Salmon W, Daughaday W. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-836.
2. Rosenbloom AL Insulin-like growth factor-I (rhIGF-I) therapy of short stature. J Pediatr Endocrinol Metab 2008; 21: 301-315.
3. Walenkamp MJ, Wit JM. Genetic disorders in the growth hormone-insulin-like growth factor-I axis. Horm Res 2006; 66: 221-230.
4. Laron Z. IGF-I and insulin as growth hormones. Novartis Found Symp 2004; 262: 56-77; discussion 77-83, 265-268.
5. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89: 1031-1044.
6. Rosenbloom AL. Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction. Endocrine 2000; 12: 107-119.
7. Rosenbloom AL. IGF-I deficiency due to GH receptor deficiency. Horm Metab Res 1999; 31: 161-171.
8. Rimoin DL. Hereditary forms of growth hormone deficiency and resistance. Birth Defects Orig Artic Ser 1976; 12: 15-29.
9. Rosenbloom AL. The role of recombinant insulin-like growth factor I in the treatment of the short child. Curr Opin Pediatr 2007; 19: 458-464.
10. Cohen P. Controversy in clinical endocrinology: problems with reclassification of insulin-like growth factor I production and action disorders. J Clin Endocrinol Metab 2006; 91: 4235-4236.
11. Norman P. Mecasermin Tercica. Curr Opin Investig Drugs 2006; 7: 371-380.
12. INCRELEX™ (mecasermin [rDNA origin] injection). 2005.
13. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D 2005; 6: 120-127.
14. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
15. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-158.
16. Camacho-Hubner C, Underwood LE, Yordam N, Yuksel B, Smith AV, Attie KM, Savage MO. Once daily rhIGF-I/rhIGFBP-3 treatment improves growth velocity in children with severe primary IGF-I deficiency: results of a multicenter clinical trial. 88th Annual Meeting of The Endocrine Society, Boston, MA, 2006; Abst OR 40-1.
17. Kaya A, Gungor K, Karakose S. Severe anaphylactic reaction to human insulin in a diabetic patient. J Diabetes Complications 2007; 21: 124-127.
18. Scheer BG, Sitz KV. Suspected insulin anaphylaxis and literature review. J Ark Med Soc 2001; 97: 311-313.
19. Gupta SK, Veith FJ, Ascer E, Wengerter KR, Franco C, Amar D, el-Gaweet ES, Gupta A. Anaphylactoid reactions to protamine: an often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery. J Vasc Surg 1989; 9: 342-350.